In our previous study, we established that esculetin, a bioactive 6,7-dihydroxy derivative of coumarin, possesses antiplatelet activity via hampering the PLCγ2-PKC cascade, hydroxyl radical formation, and Akt activation; thus, we suggested that esculetin may act as a crucial therapeutic agent for preventing thromboembolic diseases. This evidence concerns the gene PLCG2 and Thromboembolism.